Overview

Basimglurant in Children and Adolescents With TSC

Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The study intends to show that basimglurant provides effective seizure control in children and adolescents with Tuberous Sclerosis Complex (TSC).
Phase:
Phase 2
Details
Lead Sponsor:
Noema Pharma AG